Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + bevacizumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of the irreversible ErbB family blocker afatinib, the anti-VEGF monoclonal antibody bevacizumab, and the folate antimetabolite pemetrexed. It is being investigated primarily by Shandong Cancer Hospital for the treatment of patients with advanced lung adenocarcinoma who have progressed after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs). The regimen aims to overcome resistance by simultaneously inhibiting multiple ErbB receptors (EGFR, HER2, and ErbB4), blocking tumor angiogenesis via VEGF inhibition, and providing cytotoxic chemotherapy. This triplet approach is designed to address the heterogeneity of resistance mechanisms in non-small cell lung cancer (NSCLC).
- Other names
- Afatinib/Bevacizumab/Pemetrexed
02
Targets
GART (GAR transformylase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DHFR (Dihydrofolate reductase)VEGFA (Vascular endothelial growth factor A)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)TS (Thymidylate synthase)
Beyond the preview
Go deeper on afatinib + bevacizumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + bevacizumab + pemetrexed.